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Improvements in immunosuppression have modified short- term survival of deceased- 
donor allografts, but not their rate of long- term failure. Mismatches between donor 
and recipient HLA play an important role in the acute and chronic allogeneic immune 
response against the graft. Perfect matching at clinically relevant HLA loci does not 
obviate the need for immunosuppression, suggesting that additional genetic variation 
plays a critical role in both short- and long- term graft outcomes. By combining patient 
data and samples from supranational cohorts across the United Kingdom and European 
Union, we performed the first large- scale genome- wide association study analyzing 
both donor and recipient DNA in 2094 complete renal transplant- pairs with replication 
in 5866 complete pairs. We studied deceased- donor grafts allocated on the basis of 
preferential HLA matching, which provided some control for HLA genetic effects. No 
strong donor or recipient genetic effects contributing to long- or short- term allograft 
survival were found outside the HLA region. We discuss the implications for future 
research and clinical application.
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1  | INTRODUCTION
Kidney transplantation is a highly successful treatment for end- 
stage renal failure, with significant benefits for recipients both in 
survival and quality of life. Early outcomes have steadily improved 
over the last 10 years,1 with risk- adjusted and death- censored, 1- 
year renal graft survival rates of 94% and 97% for deceased and 
living donor transplants, respectively.2 However, both late allograft 
loss and increased mortality among transplant recipients remain key 
challenges for the transplant community. There are a wide num-
ber of factors that are known to influence long- term transplant 
outcome, including donor factors such as age and comorbidity, 
recipient factors such as comorbidity and response to immuno-
suppression, as well as allograft ischemic time, the degree of HLA 
mismatch, and the development of donor- specific antibodies.3-5 
However, a comprehensive understanding of the pathophysiology 
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of graft failure has remained elusive, with the observed variation in 
patient outcomes still inadequately explained by our current under-
standing of risk factors. An improved understanding of the deter-
minants of transplantation outcome would allow the development 
of truly personalized approaches to the management of transplant 
recipients.
The importance of genetic factors in transplantation has been 
clear since the inception of the technique, with the first success-
ful kidney transplant having been performed between identical 
twins in 1954. Renal transplantation between identical twins con-
tinues to show excellent long- term outcomes,6,7 and HLA match-
ing has a large impact on graft survival even in the modern era of 
immunosuppression.8
HLA genes are highly polymorphic, and demonstrate the impor-
tance of genetic variation in donor- recipient pairing that impacts on 
long- term outcomes. However, over recent decades, our ability to 
assay human genetic variation beyond the HLA region has increased 
considerably.
A number of studies have been published over recent years ex-
ploring the association between genotypes of interest and renal 
transplant outcomes.9,10 A large proportion of these studies have 
concentrated on immune- related genes, based on the hypoth-
esis that the risk of acute rejection or late allograft loss may be 
modulated by genetic variation in the immune response. As sum-
marized in Table S1, associations have been described between 
various transplant phenotypes and single nucleotide polymor-
phisms (SNPs) in a number of genes including those encoding 
tumor necrosis factor- α, interleukins- 1, - 6, and - 10, and interfer-
on- γ. Of note, many of these studies have reported inconsistent 
findings. For example, analysis of DNA from donor- recipient pairs 
in the Collaborative Transplant Study failed to replicate an earlier 
finding that particular combinations of C3 genotypes in the donor 
and recipient were associated with reduced graft survival.11,12 
While some of this discrepancy might be explained by method-
ological or populational differences between these studies, it is 
difficult to draw firm conclusions about the role of these genetic 
variations.13
More recently, attention has also focused on non- immune- related 
genetic risk variants. Donor genetic variation in CAV1 (caveolin- 1),14 
APOL1 (apolipoprotein- L1),15,16 or ABCB1 (ATP- binding cassette, sub-
family- B, member- 1, expressed in the kidney) genes 17,18 has been 
reported to be associated with increased risk of allograft failure or 
poorer recipient survival. Recipient genetic variation effects on graft 
and patient survival have only been reported in 1 cohort for CAV1.14 
In addition to effects of donor genetic variants, it might be expected 
that recipient genotypes in other pharmacometabolic pathways might 
also impact on transplant outcomes such as increased risk of acute 
rejection.19
In general, candidate gene studies in renal transplantation have 
so far failed to provide consistent and reproducible results. Some 
of the reasons for this may include small sample sizes, variations in 
genotyping methodology and strategy, and, perhaps most impor-
tantly, a lack of consistency in clinical phenotyping.20 Genome- wide 
association studies (GWAS) have contributed greatly to an increased 
understanding of complex common conditions such as inflammatory 
bowel disease, hypertension, type 2 diabetes, and schizophrenia.21 A 
small number of GWAS have been reported in the field of renal trans-
plantation, describing SNPs associated with cardiovascular adverse 
events in recipients taking calcineurin inhibitor immunosuppression,22 
2 SNPs associated with serum creatinine levels at 5 years posttrans-
plant,23 and a number of SNPs associated with the development of 
new- onset diabetes after transplantation.24 Recently, a GWAS using 
pooled DNA of recipient- only origin found variation in 2 new loci as-
sociated with acute rejection in both univariate and multivariate anal-
ysis.25 However, these studies were underpowered for discovery of 
genetic variants with small effect sizes.
The Wellcome Trust Case Control Consortium (www.wtccc.org.
uk/ccc3) has led the deployment of GWAS in a wide range of condi-
tions. As part of WTCCC- 3, all renal transplant centers in the United 
Kingdom and Ireland formed the United Kingdom and Ireland Renal 
Transplant Consortium (UKIRTC; www.ukirtc.org). Collaborative 
initiatives such as these are essential for the collection of adequate 
sample numbers, for the sharing of expertise, standardization of 
techniques, and building consensus on accurate phenotyping of 
clinical data. Through this consortium, 3936 samples comprising 
2094 complete donor- recipient pairs were tested in the GWAS 
discovery phase, and an additional 5866 complete donor- recipient 
pairs in the replication phase, making this the largest GWAS con-
ducted to date in renal transplantation outcomes.
2  | METHODS
2.1 | Discovery study participants
The large multicenter United Kingdom and Ireland Renal Transplant 
Consortium (www.UKIRTC.org), coordinated by King’s College London 
in partnership with the WTCCC- 3 and the National Health Service 
Blood and Transplant database (NHS- BT), sourced all available good- 
quality stored DNA samples and pre- existing GWAS data from both 
recipients and their corresponding donors from all renal transplan-
tation centers in the United Kingdom and the Republic of Ireland 
(listed in Table S2). The study was approved by the Hammersmith and 
Queen Charlotte’s & Chelsea Research Ethics Committee REC No 08/
H0707/1, on October 14, 2009. Third-party anonymized clinical data 
were provided by NHS-BT UK. All samples and anonymized data for 
the replication cohort were provided by the University of Heidelberg.
Following genotyping and GWAS quality control (see below), there 
were 2689 unique recipients, 2204 unique donors, and 2094 complete 
donor- recipient transplantation pairs available for analysis. Figure 1 de-
scribes the study design and analysis steps. Table 1 provides additional in-
formation for the complete donor- recipient pairs (discrepancies between 
Figure 1 and Table 1 are because some recipients received more than 1 
graft, some donors donated 2 kidneys to different recipients, and not all 
recipients had matching donor GWAS data and vice versa). The samples 
and data referred to transplants that took place between December 
1981 and December 2007.
     |  1373HERNANDEZ- FUENTES ET Al.
Inclusion criteria for the study were as follows: (1) deceased 
donor kidney transplants only; (2) recipient is an adult (>16 years old); 
(3) reported European ancestry for recipients; and (4) graft survival 
time >3 months. Donor- recipient allocation followed NHS- BT stan-
dard UK- protocols during the study period.
2.2 | Replication phase participants
A cohort of 5866 complete donor- recipient pairs, with similar ethnicity 
to that of the discovery study, were obtained from the Collaborative 
Transplant Study DNA Biobank held at the University of Heidelberg, 
Germany (Table 1).
Clinical variables, datasets, and analysis are described in 
Supplementary Methods.
2.3 | Discovery phase genotyping and analysis
A whole genome amplification step was undertaken (Source BioScience, 
Nottingham) for samples containing 5- 40 μL of DNA (n = 990 samples). 
Samples were assayed via Illumina 670 Quad Custom GWAS chips, and 
subjected to standard postgenotyping quality control procedures before 
being imputed to the 1000- genomes reference dataset. Imputation of HLA 
alleles from SNP genotype data was undertaken using HLA*IMP software26 
and compared to serologically typed alleles. A series of GWAS analyses were 
performed to investigate different genetic models and the renal transplant 
outcomes of interest. Graft survival genome- wide analyses were performed 
(using Cox proportional hazards modeling) for (1) donor SNP genotype 
main effects; (2) recipient SNP genotype main effects; (3) donor*recipient 
SNP genotype interaction effects (1df and 3df tests); and (4) CNV- 
 tag- SNPs genotype mismatch effects (2 different models). Acute rejec-
tion genome- wide analyses were performed (using logistic regression) 
for models (1)-(3). An end- stage renal failure genome- wide analysis was 
performed (using logistic regression) for model (2), and to take advantage 
of the opportunity, an intracranial hemorrhage genome- wide analysis was 
performed (using logistic regression) for model (1).
2.4 | Replication- phase genotyping and analysis
Replication DNA samples were received at King’s College London and 
sent to the Wellcome Trust Sanger Institute for replication analysis. A 
F IGURE  1 Analysis workflow and strategy. Main input cohorts, analysis methods, and sample sizes are indicated. For binary traits, numbers 
indicate samples with/without the trait. For further details, see Methods and Supplementary Methods. GWAS, genome- wide association 
studies; WTCCC, Wellcome Trust Case Control Consortium
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replication panel of 139 SNPs (post–quality control) was tested based 
on a combination of low P value (<10−6) from the discovery phase, 
plus good support of association signals from SNPs in local linkage 
disequilibrium (LD), or on prior candidature from previous association 
studies. SNPs were tested according to the same model as motivated 
their inclusion in the replication panel (for example, if nominated 
based on a low P value for acute rejection in recipients, then that was 
also the test of interest in the replication analysis). Meta- analysis of 
discovery and replication results was carried out using inverse vari-
ance meta- analysis.27
For further details see Figure 1 and the Methods section in the 
Supplementary Material.
2.5 | Role of the funding source
The funding sources did not participate in the study design, collection, 
analysis or interpretation of the data, nor did they have a role in writ-
ing the report or the decision to submit for publication.
3  | RESULTS
3.1 | SNP association analysis
Despite the large size of our study (Table 1 and Table S2), 
none of the phenotypes and genetic models tested in the 
TABLE  1  Indicative renal transplant demographics from WTCCC3 and the validation cohort. For consistency, numbers refer to transplants 
where both donors and recipients passed QC (“complete” donor- recipient pairs)
WTCCC3 (post QC) % Replication cohort %
Total transplants where both donors and 
recipients passed QC
2094 100 5866 100
Total unique donors with a paired recipient 1850 100 5027 100
Total unique recipients with a paired donor 2086 100 5866 100
Mean donor age ± SD 43 ± 15.4 43 ± 16.7
Mean recipient age ± SD 45 ± 13.3 48 ± 13.6
0 previous grafts 1864 89 N/A
1 previous graft 204 9.7 N/A
2 or more previous grafts 26 1.2 N/A
Graft survival time (days- to- uncensored- event, 
25% quartile)
902 442
Graft survival time (days- to- uncensored- event, 
median)
1866 1769
Graft survival time (days- to- uncensored- event, 
75% quartile)
3165 3162
0 HLA mismatches 223 10.7 N/A
1 or 2 Class I HLA mismatches 839 40.1 N/A
1 or 2 Class II HLA mismatches 20 0.96 N/A
1 or 2 mixed Class I/II HLA mismatches 124 5.9 N/A
3 to 5 HLA mismatches 612 29.2 N/A
6 HLA mismatches 8 0.4 N/A
N/A HLA mismatches 268 12.8 N/A
Graft survival: total uncensored 495 23.6 2951 50.3
Graft survival: total censored 1599 76.4 2915 49.7
Total double- kidney transplants 3 0.14 N/A
Total en bloc kidney transplants 1 0.05 N/A
Total kidney+pancreas transplants 16 0.76 N/A
Total kidney- only transplants 2074 99.0 N/A
Total rejections (first 3 mo) 259 12.4 N/A
Total no rejections (first 3 mo) 915 43.7 N/A
N/A rejections (first 3 mo) 920 43.9 N/A
Total rejections (3- 12 mo) 221 10.6 575 9.8
Total no rejections (3- 12 mo) 946 45.2 2573 43.9
N/A rejections (3- 12 mo) 927 44.3 2718 46.3
N/A, data not available; QC, quality control; WTCCC3, Wellcome Trust Case Control Consortium- 3.
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discovery phase produced any LD- supported single- SNP re-
sults of genome- wide significance (P ≤ 5 × 10−8). We also per-
formed a partitioned heritability analysis via stratified LD score 
regression,28 which failed to reveal any significant enrichment 
of heritability in genomic regions marking tissue- or cell- type- 
specific activity (Figure 2).
We pursued a second “replication” phase in the hope that the most 
significant SNPs would be enriched for true association signals. One 
F IGURE  2 Partitioned heritability analysis of graft survival GWAS results. X- axis indicates –log10 (P value) for a test for heritability 
enrichment within 10 cell/tissue- type categories of genomic annotations, marking tissue- or cell- type- specific activity. Dotted lines indicate 
Bonferroni significance level. (A) Death treated as a censored event; (B) death treated as a failure event. CNS, central nervous system
A
B
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hundred thirty- nine SNPs (post–quality control) were tested, based 
either on a low P value from the discovery phase plus LD support or 
on prior candidature from previous association studies. In general, the 
distribution of replication P values for all the tests did not depart ap-
preciably from that expected under a global null hypothesis (Table S3). 
There was some enrichment for low P values in the recipient genotype 
main effect tests for acute rejection in the 12 months following trans-
plantation. However, the P values from meta- analysis (across both dis-
covery and replication phases) did not reach genome- wide significance 
(P ≤ 5 × 10−8). The single SNP with strongest evidence for association 
was rs2289887 (Figure S1 and Table S4), which had consistent effects 
in both cohorts but a meta- analysis P value of only 0.00011, indicating 
that further studies are needed to establish the validity of this signal.
We collated all previously published association signals for early 
graft rejection and long- term allograft survival and none of these rep-
licated in our study (Table S1).
3.2 | HLA mismatch analysis
We took advantage of recorded serological information to check for 
known associations with donor- recipient mismatch levels and to com-
pare recorded information with imputed mismatches based on SNP 
genotype information (Figure 3). As expected for deceased donor 
transplants, the number of non- zero mismatch transplants in our data 
was low, reducing our power to detect associations. Nevertheless, we 
confirmed significant associations with HLA- A (P = .022) and HLA- 
DRB (P = .00049) mismatches using the recorded data.
On the other hand, the imputed mismatch results did not reproduce 
the expected associations. We attribute this to 2 factors: (1) the true 
mismatch = 2 frequency was low, due to donor selection; (2) as with any 
statistical noise, the imputation inaccuracy tended to act with dispropor-
tionate effect in the extremes of the distribution (here, the mismatch = 2 
group), resulting in higher relative errors in that group. Thus, although the 
overall imputation accuracy was high (Tables S5 and S6), the rate of false 
positives was disproportionately high in the mismatch = 2 categories, 
swamping our ability to detect the true association signals (Table S7).
4  | DISCUSSION
In this article, we report the results of the first large- scale GWAS in 
renal transplantation. Despite our considerable sample size, we did not 
replicate any proposed findings from previous candidate gene studies 
nor did we discover any convincing new variants in our own analyses. 
There are a number of plausible reasons that may explain this.
Firstly, although this was a study involving thousands of individu-
als, by GWAS standards it was at the lower end of the range of sample 
sizes that have been employed for other human traits.29,30 A decade of 
GWAS across multiple complex traits has shown that single effect sizes 
for any 1 causal variant are typically low, and thus for some traits even 
bigger sample sizes than ours are needed to discover them. For ex-
ample, the first robustly associated locus for schizophrenia was found 
in a discovery GWAS cohort of 3322 cases and 3587 controls.31 The 
number of reliably associated signals for schizophrenia has now grown 
F IGURE  3 Kaplan- Meier plots of graft survival by number of mismatches by serological typing (A, B, and C), imputed 2- digit resolution (D, E, 
and F), and imputed 4- digit resolution (G, H, and I). P values were obtained from likelihood ratio tests on Cox proportional hazards models
     |  1377HERNANDEZ- FUENTES ET Al.
to 108, providing new biological insights into the disease, thanks to 
a meta- analysis that involved 40 000 cases and 113 000 controls.32
Secondly, part of our study sought to look for recipient- donor ge-
netic interactions. Interaction effects require even larger sample sizes 
to be reliably discovered. With a few notable exceptions,33 GWAS 
studies on other traits have been unsuccessful in discovering reliable 
interaction effects.
Thirdly, and perhaps most importantly, the transplantation out-
comes we considered were relatively crude measures obtained retro-
spectively from national registry data, collected over many years for 
reasons other than for acting as endpoints in a genome- wide asso-
ciation study. Our outcomes were therefore heterogeneous, subject 
to missingness, and subject to environmental factors that likely weak-
ened the genetic signals. Graft survival time is expected to be sub-
ject to a range of factors including graft quality, drug regimen, patient 
compliance, changes in standard- of- care over time, between- center 
differences, and underlying biological causes of renal dysfunction. 
Additionally, a substantial proportion of the survival time data were 
right- censored (60.5%- 76.4%, depending on model being fitted), re-
ducing the power for this endpoint.
Acute graft rejection is also a heterogeneous phenotype arising from 
various immune and nonimmune biological causes. Furthermore, this 
phenotype was derived from a field that in many records was left blank, 
resulting in a high degree of missingness (56.7%- 58.3%, depending on 
model being fitted). The high missingness rate reduced the power of our 
study, and nonrandom missingness would complicate the interpretation 
of any positive association signals we might have found (although we 
note the nonrandom missingness bias would need to be the same in 
both the discovery and replication cohorts for a signal to be replicated).
Batch effects are also a concern. Both the discovery and replica-
tion data were obtained from multiple different collection points in 
different countries over many years, and thus our phenotypes may be 
subject to batch effects, for example, arising from different treatment 
protocols over time and space. Genetic data can also be subject to 
batch effects, for example, arising from differences in sample collec-
tion protocols and unknown differences in population structure. We 
applied both covariate selection and genetically derived principal com-
ponent axes to try to mitigate such effects. We also note that, as with 
nonrandom missingness, the batch effect structure would need to be 
the same in both the discovery and replication cohorts in order for 
false- positive association signals to be replicated. Nevertheless, to-
gether these extraneous factors may well have increased the noise in 
our data, and so reduced (and made less detectible) the genetic effects 
in our data.
HLA imputation from chip- based genetic data might in time be of 
value as an adjunct to serological typing. However, our investigations 
found that the additional noise introduced by imputation uncertainty 
prevented the imputed data from picking up the well- known mismatch 
signals at HLA- A and HLA- DRB. This suggests that the accuracy of 
HLA imputation will need to be improved before it can be used reliably 
as an alternative to serotyping.
In contrast, our serological data successfully detected the HLA- A 
and HLA- DRB mismatch signals, despite the reduced power to do so 
resulting from HLA- matching of deceased donor allografts. This indi-
cates that, despite the various shortcomings of our study, strong HLA 
signals were detectable in our data. The implication therefore, at least 
as far as our primary graft survival endpoint is concerned, is that sig-
nals outside the HLA region are weaker than those already established 
in the HLA region. We therefore anticipate that genetic effects outside 
of the HLA region are more likely to be of value in elucidating biologi-
cal pathways than in direct clinical prediction.
We explored this last point further via formal power calculations. 
These indicated that we were well powered to detect any main ef-
fect graft survival association signals involving causal SNPs with 
allelic hazard ratios in the range 1.4- 1.9 (log- additive risk model, 
alpha = 5 × 10−8, power = 0.8, minor allele frequency>0.05), and to 
detect main- effect acute rejection association signals with allelic odds 
ratios in the range 1.7- 2.9. We emphasize that these effect sizes are 
applicable to the traits investigated in this study, but that larger effects 
might be found in future studies under more precise phenotyping.
In summary, while our study was able to replicate known mismatch 
signals in the HLA region, we failed to find convincing association sig-
nals outside of the HLA region. Both phenotype heterogeneity and 
sample size may have contributed to this result. Looking ahead, we 
note that the general lessons from GWAS applied to multiple human 
traits over more than a decade have brought home 3 clear mes-
sages.29,30 The first is that all complex traits contain a genetic com-
ponent, and harbor a large number of causal variants throughout the 
genome. The second is that larger GWAS studies, often obtained via 
meta- analysis with previous studies, inevitably succeed in discovering 
some portion of these causal variants. The third is that when a large 
enough portion of these variants is discovered, new insights into the 
biology of the trait are gained. With these points in mind, we look 
forward to an international consortium (iGeneTrain34), which has been 
formed to share and meta- analyze genetic and phenotypic data from 
most major transplant cohorts worldwide. We also look forward to ef-
forts to collect more detailed phenotypes of relevance to transplant 
failure, which should provide greater genetic resolution. The data pro-
vided by our study form a foundation for ongoing efforts seeking to 
uncover the biology and improve the prospects for renal transplanta-
tion outcomes.
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